As an experimental hyperlipemic model used to screen anti-hyperlipemic agents, a high lipid diet containing cholesterol has been fed to various species (1) (2) (3) (4) (5) . It is known that rats (2) exhibit only a slight increase in serum lipid levels as compared with the very high increase in serum lipids observed in rabbits (1) . The difference in these responses to dietary lipids may be attributed to the abilities to absorb or metabolize lipids.
We carried out studies on experimental nephritis in rats and focused on the fact that the serum cholesterol level was remarkably increased in nephritis induced by i.v. adminis tration of anti-kidney serum (6, 7) . In these reports, it was also demonstrated that this experimental nephritis was characterized by hyperproteinuria, hyperenzymuria, hypo proteinemia and massive edema as well as hypercholesterolemia and belonged to the so called "nephrotic type".
In the present studies, findings in hyperlipemic rats given i.v. a small dose of anti-kidney serum and fed a cholesterol diet were compared with those either fed the cholesterol diet or given a large dose of anti-kidney serum. The effect of known anti-hyperlipemic agents and glucocorticoids with previously demonstrated proteinuria reducing action in nephrotic syndrome in man and experimental animals was also tested on the hyperlipemia of the three models employed.
MATERIALS AND METHODS

Experimental hyperlipemia
The following three hyperlipemic models were produced in male Wistar rats grouped into 6.
Group A: Rats weighing approx. 100 g were fed a solid cholesterol diet prepared in accordance with the report of Seskind et al. (2) . This food consisted of 1 % cholesterol, 0.2 % sodium cholate and 0.5 % olive oil and the animals ingested only this diet up to the time of sacrifice.
Group B: Rats weighing approx. 120 g were given i.v. 0.7 ml/100 g body weight of
anti-kidney rabbit serum (anti-kidney serum) prepared by the method of Heymann and Lund (8).
Group C: After the rats weighing approx. 100 g had ingested the cholesterol diet for one week, they were given 0.3 ml/100 g body weight i.v., of anti-kidney serum and the chol esterol diet was again provided.
Determination of contents of serum lipids and urine protein Animals were kept in individual metabolic cages for 24 hr before the collection of blood samples. During the urine collection, the animals were allowed only water ad libitum.
Following the urine collection, they were fixed in a supine position anesthetized with ether and a laparotorny was quickly performed. The blood was collected from the abdominal aorta and serum was separated by centrifuging in the cold. The contents of total lipid, triglyceride, phospholipid, cholesterol and (3-lipoprotein in serum were determined by the methods of Huerga (9), Handel and Zilversmit (10), Fiske and Subbarow (11), Zurkowski (12) and Antoniades et al. (13) , respectively. Urine protein was quantitatively determined according to the method of Kingsbury et al. (14) . Each serum lipid content was expressed as mgf dl serum. Urine protein content was expressed as mg/24 hr urine.
The effects of test drugs on serum lipid levels and urine protein excretion were examined in three hyperlipemic models of groups A, B and C each comprising 6 rats. To the animals of group A, each test drug dissolved or suspended in 1 % gum arabic solution was admin istered p.o. once daily from the first day of provision of the cholesterol diet to the 6th day (total 7 administrations) and on the 7th day, the evaluation of each drug was carried out.
To the animals of groups B and C, each test drug was administered p.o. once daily until the 6th day after the anti-kidney serum injection (total 7 administrations). On the 7th day, these rats were sacrificed and the evaluation of each drug was carried out. Normal and control groups were given p.o. the same volume of 1 % gum arabic solution. The efficacy of each test drug was expressed as a percent inhibition as shown in the Tables.
Drugs
The following drugs were used. 
RESULTS
Changes in serum lipid levels after the start of a cholesterol diet in group A rats Changes in serum lipid levels determined weekly until the 8th week following the start of the cholesterol diet in group A are illustrated in Fig. 1 Changes in serum lipid levels and urine protein excretion after the injection of anti-kidney serum in group B rats Serum lipid levels and urine protein excretion in group B were determined at various intervals until the 30th day following the injection of anti-kidney serum. As illustrated in Fig. 2 , serum total lipid, phospholipid and cholesterol levels already reached their peaks on the day following the injection of anti-kidney serum (1st day), being 452, 219 and 287
higher than normal levels, respectively. Serum triglyceride level also increased markedly from the 1st day and reached a peak (559 % higher than normal level) on the 7th day. These four parameters then decreased gradually and reached the increase rates of 50-100 % on the 30th day. Urine protein excretion brought about very sharp increases of 4202 % on the 1st day. Thereafter, the high level was maintained, being 1313 % higher than normal level, even on the 30th day. Changes in serum lipid levels and urine protein excretion after the infection of anti-kidney serum in group C rats
As illustrated in Fig. 3 , serum total lipid and cholesterol levels in group C already reached their peacks on the 3rd day when determined at the appropriate intervals from the 3rd day to the 30th day. Such were 964 and 1423 % higher than normal levels, respectively. The latter in particular brought about the highest increase rate of serum lipids determined. Both levels then continued to decline but were 3 times higher than normal levels even on the 30th day.
On the other hand, the increase rate of triglyceride level in serum was low, compared with increase rates of above two lipids but reached a peak on the 5th day (244 % higher than normal level). The triglyceride level thereafter decreased and on the 30th day, a significant increase was no longer observed. Serum phospholipid and ;3-lipoprotein levels were 531 and 687 % higher than normal levels on the 10th day, respectively. On the 30th day, approx.
twice the level in the former and approx. 4 times the level in the latter were noted. Thus the increase rates of all serum lipid levels except for triglyceride were higher in this group than in group B throughout the experimental periods. On the contrary, the excretion of protein into the urine in this group was less than that in group B. On the 3rd day, urine protein excretion showed a sharp increase of 3530%. However, this level then decreased rapidly and on the 30th day, remained at the increased rate of 668 %.
Effects of anti-hyperlipemic drugs and glucocorticoids on serum lipid levels in group A rats
The serum total lipid and cholesterol levels were determined to evaluate the anti hyperlipemic effect of test drugs. As shown in Table 1 , none of anti-hyperlipemic agents and glucocorticoids exhibited significant inhibitory effects on any of serum lipids. Effects of anti-hyperlipemic drugs and glucocorticoids on serum lipid levels and urine protein excretion in group B rats Serum lipids, total lipid, triglyceride and cholesterol levels were determined. As shown in Tables 2 and 3 , clofibrate (100 mg/kg/day) had the most potent anti-hyperlipemic effect, inhibiting total lipid, triglyceride and cholesterol levels by 29.2, 38.8 and 20.8 %, respectively.
Furazabol (1 mg/kg/day) and (3-sitosterol (500 mg/kg/day) showed a significant inhibitory effect only on cholesterol and triglyceride levels, respectively. However, ethyl linoleate (500 mg/kg/day) was ineffective in this model. Prednisolone (10 mg/kg/day) and betame thasone (0.2 mg/kg/day), glucocorticoids, resulted in more potent effects than clofibrate in inhibiting the serum levels of these three kinds of lipids. Prednisolone and betamethasone also had a potent inhibitory effect of 70.3 and 55.8 %, respectively on urine protein excretion.
On the other hand, none of anti-hyperlipemic agents tested significantly inhibited the urinary excretion of protein.
Effects of anti-hyperlipemic drugs and glucocorticoids on serum lipid levels and urine protein excretion in group C rats Serum lipids, total lipid, triglyceride, cholesterol and (3-lipoprotein were quantitatively determined and results are shown in Tables 4 and 5 . Clofibrate (100 mg/kg/day) inhibited total lipid, triglyceride, cholesterol and (3-lipoprotein levels by 35.5, 57.4, 43.5 and 40.7%, respectively, thus resulting in a more potent anti-hyperlipemic effect in this group as compared to group B. Furazabol (1 mg/kg/day) had almost the same inhibitory effect as clofibrate on all serum lipid levels determined, although the effectiveness was less in group B. i3 sitosterol (500 mg/kg/day) significantly inhibited triglyceride and cholesterol levels, exhibi ting more potent anti-hyperlipemic effects in this group than in group B. Of anti-hyperlipe mic agents tested, only ethyl linoleate (500 mg/kg/day) had little effect even in this group.
Prednisolone (10 mg/kg/day) and betamethasone (0.2 mg/kg/day) showed strong inhibitory effects on all lipid levels determined. The urinary protein excretion was strongly inhibited by both steroids, whereas it was not affected by anti-hyperlipemic agents. On the other hand, as described to some extent in our previous report (6) , marked increases of serum total lipid, triglyceride, phospholipid and cholesterol levels were observed in experimental nephrotic syndrome induced in rats by the injection of anti-kidney serum.
Matsuda and Kalant (16) demonstrated that the cholesterol level in the arterial walls of rats with anti-kidney serum induced nephrotic syndrome was higher than that in arterial walls of rats fed only the high-lipid diet. Their observations suggest that nephrotic hyperlipemic rats may be more prone to atherosclerosis. The mechanism of development of the hyper lipemia in nephrotic syndrome has not been yet clearly established. Marsh and Drabkin (17, 18) observed that in vitro incorporation of [1-14C] acetate into cholesterol by liver slices was increased the 2nd day after anti-kidney serum injection but on the 6th day, despite marked hyperlipemia, incorporation into cholesterol as well as total liver fatty acid fell below normal. It is unlikely, therefore, that an increase in lipid synthesis by the liver produces a hyperlipemia. The same workers also reported that, while the cholesterol levels in blood, liver and kidney were increased in anti-kidney serum induced nephrotic syndrome, the level of this substance in the remainder of the body was correspondingly decreased and the total cholesterol level in the body remained relatively constant (17) . It is suggested that the hyperlipemia in the experimental nephrotic syndrome may be the mobilization of lipids from storage in other tissues. It has also been shown that in clinical and experimental nephrotic syndrome, the lipoprotein lipase activity (19) and the esteri fication of free fatty acids (20) are decreased. When anti-hyperlipemic agents were tested, only clofibrate exhibited significant inhibitory effects on any of serum lipids determined.
Furazabol and (3-sitosterol were effective only on serum cholesterol and triglyceride levels, respectively. Interestingly, the glucocorticoids, prednisolone and betamethasone, proved to have more anti-hyperlipemic activity than clofibrate. These glucocorticoids seem to secondarily exert the anti-hyperlipemic effect by inhibiting the development of nephritis, because both drugs also exhibited a potent antiproteinuric effect. As the inhibition of lipogenesis by glucocorticoids has been reported by Eisenstein (21) , the anti-hyperlipemic effect of both drugs may be partly due to their inhibitions of lipid biosynthesis. On the other hand, it is known that prolonged glucocorticoid treatment results in elevated plasma lipid levels and produces fatty liver as well as fat accumulation on the face of humans and experimental animals. Therefore, glucocorticoids can hardly be recommended for the treatment of atherosclerosis which requires long term therapy.
In another experiment, we tried to produce a hyperlipemic model (group C) which is more sensitive to various types of anti-hyperlipernic agents by combining the i.v. adminis tration of a small dose of anti-kidney serum and the feeding of the cholesterol diet. Although the proteinuria of this group was less than that of group B, the increase rates of serum total lipid, phospholipid, cholesterol and 9-lipoprotein levels were by far higher in this group than in groups A and B. In addition, the increases of all serum lipids except for triglyceride were synergistic, since in a preliminary experiment, no appreciable elevations of these serum lipids were observed with anti-kidney serum (0.3 ml/100 g body weight) alone. The syn ergistic increases of these lipids may be partly due to the daily increased intake of the choles terol diet, because rats with nephrotic syndrome have a vigorous appetite which compensates for the considerable loss of plasma protein into the urine. However, the exact mechanism of the hyperlipemic synergism remains unclear. When given in group C, various types of anti-hyperlipemic agents tested (furazabol, clofibrate and (3-sitosterol) were effective for the hyperlipemia but were ineffective for the proteinuria. Moreover, this model was more sensitive to these anti-hyperlipemic agents than was group B.
